Insulin‐like growth factor I and risk of incident cancer in elderly men – results from MrOS (Osteoporotic Fractures in Men) in Sweden

Studies of the association between circulating IGF‐I and cancer risk have shown conflicting results. We have previously observed a U‐shaped association between IGF‐I and cancer mortality. This study test the hypotheses of a U‐shaped association between IGF‐I and incident cancer.

[1]  D. English,et al.  Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[2]  Ross J. Harris,et al.  Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis , 2009, International journal of cancer.

[3]  A. Yashin,et al.  Increase in circulating levels of IGF‐1 and IGF‐1/IGFBP‐3 molar ratio over a decade is associated with colorectal adenomatous polyps , 2012, International journal of cancer.

[4]  Nils Lid Hjort,et al.  Model Selection and Model Averaging: Contents , 2008 .

[5]  D. Albanes,et al.  No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[6]  R. Hayes,et al.  IGF‐1 and IGFBP‐3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial , 2007, International journal of cancer.

[7]  François G. Meyer,et al.  Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.

[8]  M. Spitz,et al.  Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[10]  E. Varenhorst,et al.  Validity of a Population-Based Cancer Register in Sweden An Assessment of Data Reproducibility in the South-East Region Prostate Cancer Register , 2003, Scandinavian journal of urology and nephrology.

[11]  M. Petzold,et al.  Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  Noel S Weiss,et al.  Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin , 2005, Cancer.

[13]  A. Whittemore,et al.  Prostate Cancer Risk in Relation to Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Prospective Multiethnic Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  S. London,et al.  Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. , 2002, Journal of the National Cancer Institute.

[15]  F. Berrino,et al.  Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. , 2007, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  J. Cerhan,et al.  IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[17]  R. Hayes,et al.  Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma , 2012, International journal of cancer.

[18]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[19]  Jenny Donovan,et al.  Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. , 2012, Cancer research.

[20]  G. Sesti,et al.  Reciprocal Association of Plasma IGF-1 and Interleukin-6 Levels With Cardiometabolic Risk Factors in Nondiabetic Subjects , 2008, Diabetes Care.

[21]  Guanghui Wang,et al.  Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis , 2012, PloS one.

[22]  E. Riboli,et al.  Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden , 2002, Gut.

[23]  P. Lips,et al.  The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[25]  Xiao-yan Gao,et al.  The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma , 2013, The Journal of international medical research.

[26]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[27]  K. Sjögren,et al.  The role of liver-derived insulin-like growth factor-I. , 2009, Endocrine reviews.

[28]  F. Clavel-Chapelon,et al.  Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studies , 2010, International journal of cancer.

[29]  M. Inoue,et al.  Plasma C‐peptide, insulin‐like growth factor‐I, insulin‐like growth factor binding proteins and risk of colorectal cancer in a nested case‐control study: The Japan public health center‐based prospective study , 2007, International journal of cancer.

[30]  W. Xu,et al.  IGF-I and IGFBP-3 and the risk of lung cancer: A meta-analysis based on nested case-control studies , 2009, Journal of experimental & clinical cancer research : CR.

[31]  E. Riboli,et al.  Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. , 2012, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[33]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[34]  G. Stemmermann,et al.  Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. , 2003, American journal of epidemiology.

[35]  N. Rifai,et al.  Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. , 2000, Annals of internal medicine.

[36]  N. Probst-Hensch,et al.  IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai , 2001, British Journal of Cancer.

[37]  M. Petzold,et al.  Both low and high serum IGF-I levels associate with cancer mortality in older men. , 2012, Journal of Clinical Endocrinology and Metabolism.